Active Surveillance for Intermediate Risk Prostate Cancer

Active Surveillance for Intermediate Risk Prostate Cancer Curr Urol Rep (2017) 18: 80 DOI 10.1007/s11934-017-0726-3 PROSTATE CANCER (S PRASAD, SECTION EDITOR) Laurence Klotz Published online: 11 August 2017 Springer Science+Business Media, LLC 2017 Abstract Genetic tissue-based biomarkers are also likely to play a role Purpose of Review Active surveillance is now widely utilized in enhancing decision making. for the management of low-risk prostate cancer (PCa). The . . limits of surveillance for men with intermediate risk cancer Keywords Prostate cancer Active surveillance are controversial. While there is a broad consensus that men Intermediate risk with low-risk disease can be safely managed with AS, many potential candidates, including those with Gleason 3 + 4 dis- ease, PSA >10, younger men and African-Americans are often Introduction excluded. Recent Findings Outcome data for intermediate-risk patients Once considered heresy, it is now widely accepted that many managed by active surveillance demonstrate reasonable out- patients with prostate cancer can be managed conservatively, comes, but these men clearly are at higher risk for progression with periodic monitoring to identify those who should be re- to metastatic disease. The use of biomarkers and classified and offered treatment. The primary parameter for multiparametric MRI will enable a more precise and person- identifying patients at http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Urology Reports Springer Journals

Active Surveillance for Intermediate Risk Prostate Cancer

Loading next page...
 
/lp/springer_journal/active-surveillance-for-intermediate-risk-prostate-cancer-kcxS0rL9LT
Publisher
Springer Journals
Copyright
Copyright © 2017 by Springer Science+Business Media, LLC
Subject
Medicine & Public Health; Urology; Nephrology
ISSN
1527-2737
eISSN
1534-6285
D.O.I.
10.1007/s11934-017-0726-3
Publisher site
See Article on Publisher Site

Abstract

Curr Urol Rep (2017) 18: 80 DOI 10.1007/s11934-017-0726-3 PROSTATE CANCER (S PRASAD, SECTION EDITOR) Laurence Klotz Published online: 11 August 2017 Springer Science+Business Media, LLC 2017 Abstract Genetic tissue-based biomarkers are also likely to play a role Purpose of Review Active surveillance is now widely utilized in enhancing decision making. for the management of low-risk prostate cancer (PCa). The . . limits of surveillance for men with intermediate risk cancer Keywords Prostate cancer Active surveillance are controversial. While there is a broad consensus that men Intermediate risk with low-risk disease can be safely managed with AS, many potential candidates, including those with Gleason 3 + 4 dis- ease, PSA >10, younger men and African-Americans are often Introduction excluded. Recent Findings Outcome data for intermediate-risk patients Once considered heresy, it is now widely accepted that many managed by active surveillance demonstrate reasonable out- patients with prostate cancer can be managed conservatively, comes, but these men clearly are at higher risk for progression with periodic monitoring to identify those who should be re- to metastatic disease. The use of biomarkers and classified and offered treatment. The primary parameter for multiparametric MRI will enable a more precise and person- identifying patients at

Journal

Current Urology ReportsSpringer Journals

Published: Aug 11, 2017

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off